Maravai Lifesciences Holdings (MRVI) Change in Accured Expenses (2020 - 2026)

Maravai Lifesciences Holdings' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$5.3 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 390.32% year-over-year to -$5.3 million; the TTM figure through Mar 2026 stood at -$11.8 million (down 632.97% YoY), while the FY2025 annual figure was -$4.6 million, up 80.51% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$5.3 million, up from -$13.5 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $24.2 million in Q1 2023, with the low at -$24.1 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $1.5 million (2025), against an average of -$578882.4.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses jumped 882.5% in 2022, then tumbled 870.77% in 2023.
• Maravai Lifesciences Holdings' Change in Accured Expenses stood at -$5.6 million in 2022, then soared by 213.99% to $6.4 million in 2023, then sank by 124.45% to -$1.6 million in 2024, then plunged by 764.07% to -$13.5 million in 2025, then jumped by 60.52% to -$5.3 million in 2026.
• Business Quant data shows MRVI's Change in Accured Expenses at -$5.3 million in Q1 2026, -$13.5 million in Q4 2025, and $1.5 million in Q3 2025.